NCIt definition : A trifunctional bispecific monoclonal antibody with potential antineoplastic activity.
Catumaxomab has two antigen-recognition sites: one for human CD3, a T cell surface
antigen; and one for human epithelial cell adhesion molecule (EpCAM), a cell surface
antigen expressed by a variety of epithelial tumor cells. In addition, the modified
Fc portion of this antibody binds Fc receptors on antigen presenting cells (APCs)
such as macrophages and dendritic cells (DCs). Catumaxomab brings T cells, EpCAM-expressing
epithelial tumor cells and APCs together into tricellular complexes, which may result
in a potent cytotoxic T-lymphocyte (CTL) response against EpCAM-expressing epithelial
tumor cells. Fc-mediated binding of APCs in the tricellular complex potentiates EpCAM
antigen presentation to T cells and the activation of anti-tumor cytotoxic T cell
functions.;
UNII : M2HPV837HO;
CAS number : 509077-98-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 509077-98-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;